Dr. Susanne Arnold, MD

Claim this profile

University of Kentucky/Markey Cancer Center

Expert in Cancer
Expert in Non-Small Cell Lung Cancer
34 reported clinical trials
70 drugs studied

Area of expertise

1Cancer
Global Leader
Susanne Arnold, MD has run 23 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
KRAS positive
2Non-Small Cell Lung Cancer
Global Leader
Susanne Arnold, MD has run 14 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
University Of Kentucky/Markey Cancer Center
Image of trial facility.
University Of Kentucky

Clinical Trials Susanne Arnold, MD is currently running

Image of trial facility.

EP0031

for Cancer

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Recruiting1 award Phase 1 & 2
Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria

More about Susanne Arnold, MD

Clinical Trial Related1 year of experience running clinical trials · Led 34 trials as a Principal Investigator · 23 Active Clinical Trials
Treatments Susanne Arnold, MD has experience with
  • Pembrolizumab
  • Cisplatin
  • Ipatasertib
  • Binimetinib
  • Paclitaxel
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Susanne Arnold, MD specialize in?
Susanne Arnold, MD focuses on Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Susanne Arnold, MD currently recruiting for clinical trials?
Yes, Susanne Arnold, MD is currently recruiting for 23 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Susanne Arnold, MD has studied deeply?
Yes, Susanne Arnold, MD has studied treatments such as Pembrolizumab, Cisplatin, Ipatasertib.
What is the best way to schedule an appointment with Susanne Arnold, MD?
Apply for one of the trials that Susanne Arnold, MD is conducting.
What is the office address of Susanne Arnold, MD?
The office of Susanne Arnold, MD is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.